Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new analysis of the TROPION-Breast02 trial finds that first-line Dato-DXd nearly tripled CNS progression-free survival compared to chemotherapy in immunotherapy-ineligible TNBC patients with brain metastases. The drug also delivered a 62.5% intracranial response rate vs. 37.5% with chemo in patients with measurable disease. These findings add to growing evidence that Dato-DXd — already FDA-approved for metastatic TNBC — can meaningfully tackle one of the disease's most feared complications.
Brain metastases are a devastating complication for patients with metastatic triple-negative breast cancer (TNBC), carrying a real-world median overall survival of just 4–7 months. New data from an exploratory analysis of the phase 3 TROPION-Breast02 trial, presented at the 2026 ESMO Congress, show that first-line datopotamab deruxtecan (Dato-DXd) offers meaningful CNS benefits in this hard-to-treat population — even for patients who hadn't received prior brain-directed therapy.
Among 61 patients with baseline brain metastases who were ineligible for immunotherapy, Dato-DXd substantially outperformed investigator's choice of chemotherapy on both CNS and systemic outcomes. Responses were seen regardless of whether patients had previously received CNS-directed therapy, and one patient achieved a complete intracranial response lasting nearly 18 months across 26 cycles of treatment.
By the Numbers:
Why it matters: Brain metastases affect roughly one-third of patients with metastatic TNBC and have historically been associated with poor outcomes. These data suggest Dato-DXd — already FDA-approved for metastatic TNBC — may offer a meaningful new option for CNS disease control, particularly for a population that is often excluded from clinical trials.
